ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on protecting patients from severe allergic reactions, has announced its participation in the 2024 Cantor Global Healthcare Conference in New York City from September 17-19, 2024. The company's leadership, including Richard Lowenthal (Co-Founder, President, and CEO) and Eric Karas (Chief Commercial Officer), will engage in a fireside chat on September 17 at 9:10 a.m. ET.
Additionally, management will conduct one-on-one meetings with investors during the conference. The fireside chat will be accessible via live webcast on the company's website, with a replay available for 90 days in the Investors & Media section.
ARS Pharmaceuticals (Nasdaq: SPRY), una compagnia biofarmaceutica focalizzata sulla protezione dei pazienti da reazioni allergiche gravi, ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference che si terrà a New York City dal 17 al 19 settembre 2024. I leader dell'azienda, inclusi Richard Lowenthal (Co-Fondatore, Presidente e Amministratore Delegato) e Eric Karas (Chief Commercial Officer), parteciperanno a una conversazione informale il 17 settembre alle 9:10 a.m. ET.
Inoltre, il management condurrà incontri individuali con gli investitori durante la conferenza. La conversazione informale sarà accessibile tramite webcast dal vivo sul sito web dell'azienda, con una registrazione disponibile per 90 giorni nella sezione Investitori e Media.
ARS Pharmaceuticals (Nasdaq: SPRY), una empresa biofarmacéutica centrada en proteger a los pacientes de reacciones alérgicas graves, ha anunciado su participación en la 2024 Cantor Global Healthcare Conference en la ciudad de Nueva York del 17 al 19 de septiembre de 2024. El liderazgo de la compañía, incluyendo a Richard Lowenthal (Co-Fundador, Presidente y CEO) y Eric Karas (Director Comercial), participará en una charla informal el 17 de septiembre a las 9:10 a.m. ET.
Además, la dirección llevará a cabo reuniones individuales con inversores durante la conferencia. La charla informal será accesible a través de una transmisión en vivo en el sitio web de la empresa, con una repetición disponible durante 90 días en la sección de Inversores y Medios.
ARS Pharmaceuticals (Nasdaq: SPRY)는 중증 알레르기 반응으로부터 환자를 보호하는 데 중점을 둔 생명공학 회사로, 2024년 9월 17일부터 19일까지 뉴욕시에서 열리는 2024 Cantor Global Healthcare Conference에 참가한다고 발표했습니다. 회사의 경영진은 Richard Lowenthal (공동 창립자, 사장 및 CEO)와 Eric Karas (상업 책임자)가 9월 17일 오전 9:10 ET에 화상 대화에 참여할 것입니다.
또한, 경영진은 회의 기간 동안 투자자와의 일대일 회의를 진행할 것입니다. 화상 대화는 회사 웹사이트에서 실시간으로 방송되며, 투자가 및 미디어 섹션에서 90일 동안 재생 가능합니다.
ARS Pharmaceuticals (Nasdaq: SPRY), une entreprise bio-pharmaceutique axée sur la protection des patients contre les réactions allergiques graves, a annoncé sa participation à la 2024 Cantor Global Healthcare Conference qui se tiendra à New York du 17 au 19 septembre 2024. Le leadership de l'entreprise, y compris Richard Lowenthal (Co-Fondateur, Président et PDG) et Eric Karas (Directeur Commercial), participera à une discussion informelle le 17 septembre à 9h10 ET.
De plus, la direction tiendra des réunions individuelles avec des investisseurs lors de la conférence. La discussion informelle sera accessible via un webinaire en direct sur le site de l'entreprise, avec un replay disponible pendant 90 jours dans la section Investisseurs et Médias.
ARS Pharmaceuticals (Nasdaq: SPRY), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, Patienten vor schweren allergischen Reaktionen zu schützen, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference in New York City vom 17. bis 19. September 2024 angekündigt. Die Unternehmensführung, darunter Richard Lowenthal (Mitbegründer, Präsident und CEO) und Eric Karas (Chief Commercial Officer), wird am 17. September um 9:10 Uhr ET an einem informellen Gespräch teilnehmen.
Darüber hinaus wird das Management während der Konferenz Einzelgespräche mit Investoren führen. Das informelle Gespräch wird live über das Unternehmenswebsite zugänglich sein, mit einer Aufzeichnung, die für 90 Tage im Bereich Investoren und Medien verfügbar ist.
- None.
- None.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Cantor Global Healthcare Conference being held September 17-19, 2024 in New York City.
Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Tuesday, September 17, 2024, at 9:10 a.m. ET. Company management will also participate in one-on-one meetings with investors.
A live webcast of the fireside chat will be available here and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy in the EU) (previously referred to as ARS-1), an epinephrine nasal spray for patients with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.
ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
FAQ
When is ARS Pharmaceuticals (SPRY) participating in the Cantor Global Healthcare Conference?
Who will represent ARS Pharmaceuticals (SPRY) at the 2024 Cantor Global Healthcare Conference?
What type of presentation will ARS Pharmaceuticals (SPRY) give at the 2024 Cantor conference?
Will there be a webcast of ARS Pharmaceuticals' (SPRY) presentation at the Cantor conference?
What is the focus of ARS Pharmaceuticals (SPRY) as a company?
